Kyverna Therapeutics
Develops miv-cel, an autologous CD19 CAR-T candidate for B-cell-driven autoimmune diseases.
$8.53
After-hours close+0.17 (+2.03%)
At close$8.36(−3.24%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 57.28%34.82M sharesInsiders 9.46%5.75M sharesOther 33.26%20.22M shares
Shares outstanding 60.80M · Float 27.53M · 45.3% free float
Institutions13F, as of Mar 31, 2026
116 holders · 34.82M shares · 28 new positions · 60 increased · 34 reduced · 16 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Gordonmd Global Investments LP | 4.24M | 6.98% | −147.0K | May 15, 2026 |
| Gilead Sciences, Inc. | 4.13M | 6.79% | 0 | May 8, 2026 |
| Bain Capital Life Sciences Investors, LLC | 3.11M | 5.12% | 0 | May 15, 2026 |
| Deerfield Management Company, L.P. (Series C) | 2.00M | 3.29% | 0 | May 15, 2026 |
| Aigh Capital Management LLC | 2.00M | 3.29% | +500.0K | Apr 30, 2026 |
| Vanguard Capital Management LLC | 1.78M | 2.93% | +1.78Mnew | May 15, 2026 |
| Price T Rowe Associates Inc /MD/ | 1.56M | 2.56% | −207.3K | May 15, 2026 |
| Balyasny Asset Management L.P. | 1.13M | 1.85% | +144.5K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Dr. Sean E. Harper (“Harper”)incl. Westlake BioPartners Fund I, L.P. (“Westlake Fund I”), Westlake BioPartners Opportunity Fund I, L.P. (“Westlake Opportunity Fund I”) +3 more | 10.50% | 4.52M | 13G | Nov 12, 2024 ↗ |
| GordonMD Global Investments LP | 7.00% | 3.06M | 13G | Nov 17, 2025 ↗ |
| Westlake BioPartners Fund I, L.P. ("Westlake Fund I") | 6.30% | 3.79M | 13G | Feb 6, 2026 ↗ |
| JPMorgan Chase & Co. | 5.50% | 2.38M | Oct 10, 2024 ↗ | |
| Bain Capital Life Sciences Opportunities III, LP | 5.40% | 3.11M | 13G | Feb 17, 2026 ↗ |
| BlackRock, Inc. | 5.10% | 3.10M | 13G | Jul 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Fred E. Cohen | director | 4.55M | 7.48% | May 29, 2026 |
| Beth C. Seidenberg | director | 891.0K | 1.47% | May 29, 2026 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10 percent owner | 869.3K | 1.43% | Dec 22, 2025 |
| Christi Shaw | director, officer: Executive Chairperson | 66.7K | 0.11% | May 29, 2026 |
| Warner Weston Biddle | director, officer: Chief Executive Officer | 58.0K | 0.10% | Mar 17, 2026 |
| Ryan Alexander Jones | officer: Chief Financial Officer | 56.0K | 0.09% | Apr 15, 2025 |
| Karen Marie Walker | officer: Chief Technology Officer | 22.6K | 0.04% | Dec 17, 2025 |
| Mert Aktar | director | 21.7K | 0.04% | May 29, 2026 |
| Ian T. Clark | director | 21.7K | 0.04% | May 29, 2026 |
| Naji Gehchan | officer: See Remarks | 18.0K | 0.03% | Mar 17, 2026 |
6 ten-percent owners hold 7.99M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 3 people have not refiled in the last 18 months (573.3K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Dec 18, 2025 | Westlake BioPartners Opportunity Fund I, L.P.10 percent owner | Purchase | 133,333 | $7.50 | 869,317 |
| Dec 18, 2025 | Beth C. Seidenbergdirector | Purchase | 133,333 | $7.50 | 869,317 |
| Dec 15, 2025 | Karen Marie Walkerofficer: Chief Technology Officer | Sale | 23,998 | $12.20 | 22,636 |
CongressHouse and Senate disclosures
Not reported.